Innovative Therapeutics: Designer Natriuretic Peptides

Laura M G Meems, John C Jr. Burnett

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Natriuretic peptides (NPs) are essential for the maintenance of volume homeostasis, and can be of myocardial, renal, and endothelial origin. Advances in peptide engineering have enabled the design of innovative designer NPs that go beyond native peptides in efficacy, specificity, and resistance to enzymatic degradation. Therefore, designer NPs provide an unparalleled opportunity for the treatment of cardiovascular disease. In this review, we report the conceptual framework of peptide engineering of the NPs that resulted in designer peptides for cardiovascular disease. We specifically provide an update on those currently in clinical trials for heart failure and hypertension.

Original languageEnglish (US)
Pages (from-to)557-567
Number of pages11
JournalJACC: Basic to Translational Science
Volume1
Issue number7
DOIs
StatePublished - 2016

Fingerprint

Natriuretic Peptides
Peptides
Cardiovascular Diseases
Therapeutics
Homeostasis
Heart Failure
Maintenance
Clinical Trials
Hypertension
Kidney

Keywords

  • designer natriuretic peptide
  • drug development
  • heart failure
  • hypertension
  • natriuretic peptide

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Innovative Therapeutics : Designer Natriuretic Peptides. / Meems, Laura M G; Burnett, John C Jr.

In: JACC: Basic to Translational Science, Vol. 1, No. 7, 2016, p. 557-567.

Research output: Contribution to journalReview article

@article{8d13c650aad54e349b42458b6ad5e4dc,
title = "Innovative Therapeutics: Designer Natriuretic Peptides",
abstract = "Natriuretic peptides (NPs) are essential for the maintenance of volume homeostasis, and can be of myocardial, renal, and endothelial origin. Advances in peptide engineering have enabled the design of innovative designer NPs that go beyond native peptides in efficacy, specificity, and resistance to enzymatic degradation. Therefore, designer NPs provide an unparalleled opportunity for the treatment of cardiovascular disease. In this review, we report the conceptual framework of peptide engineering of the NPs that resulted in designer peptides for cardiovascular disease. We specifically provide an update on those currently in clinical trials for heart failure and hypertension.",
keywords = "designer natriuretic peptide, drug development, heart failure, hypertension, natriuretic peptide",
author = "Meems, {Laura M G} and Burnett, {John C Jr.}",
year = "2016",
doi = "10.1016/j.jacbts.2016.10.001",
language = "English (US)",
volume = "1",
pages = "557--567",
journal = "JACC: Basic to Translational Science",
issn = "2452-302X",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Innovative Therapeutics

T2 - Designer Natriuretic Peptides

AU - Meems, Laura M G

AU - Burnett, John C Jr.

PY - 2016

Y1 - 2016

N2 - Natriuretic peptides (NPs) are essential for the maintenance of volume homeostasis, and can be of myocardial, renal, and endothelial origin. Advances in peptide engineering have enabled the design of innovative designer NPs that go beyond native peptides in efficacy, specificity, and resistance to enzymatic degradation. Therefore, designer NPs provide an unparalleled opportunity for the treatment of cardiovascular disease. In this review, we report the conceptual framework of peptide engineering of the NPs that resulted in designer peptides for cardiovascular disease. We specifically provide an update on those currently in clinical trials for heart failure and hypertension.

AB - Natriuretic peptides (NPs) are essential for the maintenance of volume homeostasis, and can be of myocardial, renal, and endothelial origin. Advances in peptide engineering have enabled the design of innovative designer NPs that go beyond native peptides in efficacy, specificity, and resistance to enzymatic degradation. Therefore, designer NPs provide an unparalleled opportunity for the treatment of cardiovascular disease. In this review, we report the conceptual framework of peptide engineering of the NPs that resulted in designer peptides for cardiovascular disease. We specifically provide an update on those currently in clinical trials for heart failure and hypertension.

KW - designer natriuretic peptide

KW - drug development

KW - heart failure

KW - hypertension

KW - natriuretic peptide

UR - http://www.scopus.com/inward/record.url?scp=85016096253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016096253&partnerID=8YFLogxK

U2 - 10.1016/j.jacbts.2016.10.001

DO - 10.1016/j.jacbts.2016.10.001

M3 - Review article

AN - SCOPUS:85016096253

VL - 1

SP - 557

EP - 567

JO - JACC: Basic to Translational Science

JF - JACC: Basic to Translational Science

SN - 2452-302X

IS - 7

ER -